BioSig’s PURE EP™ Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases
- None.
- None.
Insights
The introduction of BioSig Technologies' Near Field Tracking (NFT) algorithm marks a significant innovation in the field of cardiology, particularly within the subspecialty of electrophysiology. The algorithm's ability to reduce ablation time by approximately 66% is a noteworthy development, as ablation procedures are critical in treating arrhythmias such as atrial fibrillation. Shorter ablation times can lead to reduced risks for patients, lower costs for healthcare providers and increased throughput of procedures, potentially benefiting the company's financials by driving demand for the PURE EP™ Platform.
Moreover, the adoption of NFT in over 100 cases at prestigious medical centers underscores the clinical confidence in the technology and suggests a growing market penetration. As the algorithm is available by subscription, it represents a recurring revenue model that could enhance the company's financial stability and predictability. The emphasis on precision and real-time feedback aligns with the broader industry trends toward data-driven and personalized medicine.
From an industry perspective, the successful deployment and clinical adoption of BioSig's NFT algorithm could signal a shift in the competitive landscape of medical technology for cardiac procedures. The company's focus on intracardiac signal visualization and the proprietary nature of its technology could provide a competitive edge and set new standards for the quality of care in electrophysiology.
However, the long-term impact on BioSig's market share and stock performance will depend on the continued clinical success of the NFT algorithm, the scalability of its adoption across other institutions and the company's ability to maintain its technological lead amidst potential competition. It is also critical to monitor how the adoption of such technologies aligns with healthcare reimbursement policies, as this will influence hospital purchasing decisions.
From a financial standpoint, the operational efficiencies gained from the NFT algorithm could translate into significant cost savings for healthcare providers, which may lead to increased sales of the PURE EP™ Platform. The subscription model for the NFT algorithm contributes to a stable and predictable revenue stream, which is favorable for investor sentiment. As the technology gains traction, it could also open up additional revenue streams through potential licensing deals, partnerships and international expansion.
Investors should monitor the company's quarterly financial reports for increases in revenue attributed to the NFT algorithm, as well as research and development expenses that could impact profitability. The market's response to this news will likely be reflected in the company's stock price, with potential for growth if the adoption rate continues to climb and the technology proves to be a differentiator in the market.
Company sees clinical adoption and usage of its novel Near Field Tracking algorithm, proven to reduce ablation time by approximately
Westport, CT, Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that physicians have completed over 100 cases with the Near Field Tracking (“NFT”) algorithm, an innovative and proprietary feature recently launched on the Company’s PURE EP™ Platform.
Available by subscription, PURE EP™’s NFT algorithm monitors changes in the local unipolar electrogram, empowering electrophysiologists with tissue-specific feedback and color-coded characterization in real time. Since its launch in Q4 2023, the software has been leveraged at some of the largest and leading medical centers and health systems in the country.
“BioSig’s PURE EP™ Platform and its new algorithms are pioneering the way in the automatic interpretation of cardiac cellular reaction to catheter energy delivered,” commented Hicham El Masry, MD, FHRS, Cardiac Electrophysiologist at Mayo Clinic Arizona. “NFT is a unique algorithm for assessing lesion efficiency and increases my procedural efficiency and confidence when it comes to distinguishing between healthy and scar or ablated tissue. This revolutionary feature has become a critical tool during all my complex cases.”
“We are excited about the unique value we are providing our physicians, and proud to have achieved the milestone of 100 NFT cases in less than 90 days,” added Zachary Koch, Principal Advisor of Product Development at BioSig. “As the lead researcher at BioSig in the design and capabilities of NFT, I am encouraged by the algorithm’s impact on case time, safety, and efficacy. Thank you and congratulations to all the hospitals that have subscribed to our newest software and for their continued support.”
Procedures leveraging PURE EP™’s NFT algorithm exceeded its first relevant benchmark of 100 cases, led by world-renowned medical centers, including Cleveland Clinic in Cleveland, OH, Mayo Clinic in Phoenix AZ, and Texas Cardiac Arrhythmia Institute in Austin, TX.
Researchers from Cleveland Clinic presented topline clinical findings on the value of NFT at the Heart Rhythm 2023 convention held last May. Looking ahead, in collaboration with several early adopters, the Company is investigating expanded applications for NFT.
To learn more about PURE EP™’s growing suite of proprietary software-based features, click here.
About The PURE EP™ Platform
The PURE EP™ Platform serves physicians by enabling the real-time acquisition of raw cardiac signal data—absent of unnecessary noise or interference inherent in traditional approaches. By leveraging a first-of-its-kind combination of hardware and software, the PURE EP™ Platform is designed to deliver unprecedented intracardiac signal purity that pushes the boundaries of cardiac arrhythmia identification, diagnosis, and treatment.
In a blinded clinical study recently published in the Journal of Cardiovascular Electrophysiology,1 electrophysiologists rated PURE EP™ as superior to conventional systems for
The PURE EP™ Platform is currently in use at well-respected healthcare systems, including Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic, and Kansas City Heart Rhythm Institute.
About BioSig Technologies, Inc.
BioSig Technologies is a medical technology company focused on deciphering the body’s electrical signals, starting with heart rhythms. By leveraging a first of its kind combination of hardware and software, we deliver unprecedented cardiac signal clarity, ending the reliance on ‘mixed signals’ and ‘reading between the lines.’ Our platform technology is addressing some of healthcare’s biggest challenges—saving time, saving costs, and saving lives.
The Company’s product, the PURE EP™ Platform, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time signal visualization allowing physicians to perform highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy.
An estimated, 14.4 million Americans suffer from cardiac arrhythmias, and the global EP market is projected to reach
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) BioSig’s ability to regain compliance with and meet the continued listing requirements of the Nasdaq Capital Market to maintain listing of its common stock; (ii) our cost reduction plan and associated workforce reduction or other cost-saving measures not reaching the targeted reduction of cash burn by
1 Al-Ahmad, et al. (2022, September) Evaluation of a novel cardiac signal processing system for electrophysiology procedures: The PURE EP 2.0 study. https://onlinelibrary.wiley.com/doi/10.1111/jce.15250
2 Cardiac Ablation Market. (2022, December). Global Market Insights. https://www.gminsights.com/industry-analysis/cardiac-ablation
FAQ
What is the ticker symbol for BioSig Technologies, Inc.?
What is the NFT algorithm and how has it impacted medical procedures?
How many cases have been completed with the NFT algorithm?
Who commented on the impact of the NFT algorithm?
Where has the NFT algorithm been leveraged?
